A Two-part, Phase I/II, Multi-center, Double-Blind, Randomized, Vehicle-controlled Study of the Safety and Efficacy of FB2001 in Patients With Moderate to Severe Coronavirus Disease 2019 (COVID-19) Infection
Latest Information Update: 30 Nov 2022
At a glance
- Drugs Bofutrelvir (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Frontier Biotechnologies
- 24 Nov 2022 Status changed from recruiting to completed.
- 08 Aug 2022 According to a Frontier Biotechnologies media release, data from this trial were presented at the poster session of the 11th International Conference on Emerging Infectious Diseases (ICEID) 2022.
- 08 Aug 2022 Results published in the Frontier Biotechnologies Media Release.